Pergolide for Sexual Enhancement
by Serge Kreutz
Version 1.0, October 2002
Permax (generic name: pergolide mesylate) is ergot-derived medication with similarity to Parlodel (generic name: bromocriptine) and cabergoline (brand name: Dostinex). Like bromocriptine and cabergoline, pergolide can be used for sexual enhancement, or, more specifically, as support for sexual excitement, orgasm, and ejaculation.
(The following is pharmacological data from the Permax package insert. Please be aware that the dosage information applies to the treatment of Parkinson’s disease, not for sexual enhancement. Dosages for sexual enhancement are much lower than those for the treatment of Parkinson’s disease.)
Permax (pergolide mesylate) is an ergot derivative dopamine receptor agonist at both D1 and D2receptor sites. Permax is provided for oral administration in tablets containing 0.05 m, 0.25 mg, or 1 mg pergolide as the base.
Pergolide mesylate is a potent dopamine receptor agonist. Pergolide is 10 to 1,000 times more potent than bromocriptine on a milligram per milligram basis in various in vitro and in vivo test systems. Pergolide mesylate inhibits the secretion of prolactin in humans; it causes a transient rise in serum concentrations of growth hormone and a decrease in serum concentrations of luteinizing hormone. In Parkinson’s disease, pergolide mesylate is believed to exert its therapeutic effect by directly stimulating postsynaptic dopamine receptors in the nigrostriatal system.
The major route of excretion is the kidney.
Permax is indicated as adjunctive treatment to levodopa/carbidopa in the management of the signs and symptoms of Parkinson’s disease.
Administration of Permax should be initiated with a daily dosage of 0.05 mg for the first 2 days. The dosage should then be gradually increased by 0.1 or 0.15 mg/day every third day over the next 12 days of therapy. The dosage may then be increased by 0.25 mg/day every third day until an optimal therapeutic dosage is achieved.
Permax is usually administered in divided doses 3 times per day. During dosage titration, the dosage of concurrent l-dopa/carbidopa may be cautiously decreased.
In clinical-studies, the mean therapeutic daily dosage of Permax was 3 mg/day. The average concurrent daily dosage of l-dopa/carbidopa (expressed as l-dopa) was approximately 650 mg/day. The efficacy of Permax at doses above 5 mg/day has not been systematically evaluated.
Store at controlled room temperature, 59 to 86° F (15 to 30° C ).
US law prohibits dispensing without prescription.
***
Pergolide for Sexual Enhancement
Symptomatic Hypotension and Hallucinosis
Overdosage, Serious Inflammation and Fibrosis
Kacip fatimah raises libido by increasing testosterone levels in women